Cullinan Therapeutics to Participate in Upcoming Investor Conferences
Cullinan Therapeutics (CGEM) will participate in fireside chats at the Stifel and UBS investor conferences in November 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cullinan Therapeutics (CGEM) will participate in fireside chats at the Stifel and UBS investor conferences in November 2026. CEO Nadim Ahmed and Chief Medical Officer Jeffrey Jones will speak at the Stifel 2026 Healthcare Conference in New York on November 10 at 2:40 p.m. ET and the UBS Global Biopharma Conference 2026 in London on November 17 at 2:00 p.m. GMT (9:00 a.m. ET). Webcasts will be available on the company’s investor relations website.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced that members of its management team will participate in fireside chats at the following upcoming investor conferences:
- Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the Stifel 2026 Healthcare Conference in New York, NY on Tuesday, November 10, 2026, at 2:40 p.m. ET.
- Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the UBS Global Biopharma Conference 2026 in London, UK on Tuesday, November 17, 2026, at 2:00 p.m. GMT (9:00 a.m. ET).
Webcasts of the fireside chats will be available under the Events and Presentations section of the Company’s investor relations website at https://investors.cullinantherapeutics.com/events.
About Cullinan Therapeutics
Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is a biopharmaceutical company developing potential first- or best-in-class, disease-modifying T cell engagers for autoimmune diseases and cancer. Cullinan pursues promising therapeutic targets while leveraging core expertise in T cell engagers, which are established in oncology and are now advancing into autoimmune diseases. With a clinical-stage pipeline built on a rigorous scientific approach and purposeful innovation, Cullinan is advancing its mission to deliver new standards of care for patients. Learn more about Cullinan at https://cullinantherapeutics.com/, and follow Cullinan on LinkedIn and X.
Contacts:
Investors
Nick Smith
+1 401.241.3516
Nsmith@cullinantx.com
Media
Rose Weldon
+1 215.801.7644
Rweldon@cullinantx.com
